Ginsenoside Rd Ameliorates Glucose Metabolism by Regulating GLP-1/MAPK/NF-κB Signaling Pathway in db/db Mice

Area of Science:

• Pharmacology
• Endocrinology
• Molecular Biology

Background:

• Ginsenoside Rd demonstrates therapeutic potential for type 2 diabetes mellitus (T2DM).
• The precise molecular mechanisms underlying Ginsenoside Rd's effects on T2DM remain largely unelucidated.
• This study investigates the role of inflammation in the pancreas and intestine in mediating Ginsenoside Rd's T2DM-ameliorating effects.

Purpose of the Study:

• To elucidate the mechanism of action of Ginsenoside Rd in T2DM.
• To investigate the modulation of the GLP-1/MAPK/NF-κB signaling pathway by Ginsenoside Rd.
• To assess the impact of Ginsenoside Rd on inflammatory responses in the pancreas and intestine.

Main Methods:

• Metabolic indicators of T2DM were monitored in db/db mice.
• GLP-1 and GLP-1R levels were assessed using immunohistochemistry, Western blotting, and PCR.
• Inflammatory markers (AMPK, Sirt1, MAPK, NF-κB) were analyzed via ELISA, transcriptomics, Western blot, and PCR.
• In vitro experiments were conducted to further investigate the GLP-1 signaling pathway.

Main Results:

• Ginsenoside Rd treatment led to decreased blood glucose and improved insulin resistance in db/db mice.
• Expression of GLP-1 and GLP-1R was significantly upregulated post-treatment.
• Transcriptome analysis revealed alterations in inflammatory response pathways.
• Increased AMPK phosphorylation and decreased MAPK phosphorylation were observed, consistent with in vitro findings.

Conclusions:

• Ginsenoside Rd shows promise in ameliorating T2DM in a mouse model.
• The therapeutic effects may involve the inhibition of pancreatic and intestinal inflammation.
• Promotion of GLP-1 secretion appears to be a key mechanism mediating Ginsenoside Rd's action.